Back to top
more

SiBone (SIBN)

(Real Time Quote from BATS)

$13.94 USD

13.94
16,122

+0.45 (3.34%)

Updated Nov 4, 2024 10:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings

Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

Cencora (COR) to Report Q2 Earnings: What's in the Cards?

Cencora's (COR) second-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Rising Demand Likely to Aid GE HealthCare's (GEHC) Q1 Earnings

GE HealthCare's (GEHC) first-quarter results are expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings

Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.

Is a Beat Likely for West Pharmaceutical (WST) in Q1 Earnings?

West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

Is a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?

The strong adoption of transcatheter heart valves is expected to have led to Edwards Lifesciences' (EW) growth in the first quarter.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q1 Earnings?

Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

What's in Store for Cooper Companies (COO) in Q1 Earnings?

Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.

What's in Store for Patterson Companies (PDCO) in Q3 Earnings?

Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.

What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?

DENTSPLY SIRONA's (XRAY) fourth-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 42.86% and 2.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Earnings Preview: Masimo (MASI) Q4 Earnings Expected to Decline

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hologic's (HOLX) Q1 Earnings Beat Estimates, Gross Margin Down

Hologic's (HOLX) Breast Health segment registered strong growth in Q1, primarily owing to higher capital equipment revenues.

Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls

Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.

Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise

Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q4 Earnings?

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?

Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.

Hologic (HOLX) Q1 Earnings Might Rise on Breast Health Growth

Strong performance in the Breast Health segment is likely to boost Hologic's (HOLX) Q1 result.

Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store?

Quest Diagnostics' (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.